# FMT in Triple Negative Breast Cancer Guided by ctDNA

Source: https://onco.cc/trials/nct07292142/  
OnCo record `nct07292142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Jewish General Hospital, not yet recruiting.

## Summary

FMT in Triple Negative Breast Cancer Guided by ctDNA is a phase 1/2, interventional study registered as NCT07292142 by Jewish General Hospital, with a registry enrolment figure of 125 participants, started 2026-02 and due to reach its primary completion in 2029-12. Interventions recorded: Fecal Microbiota Transplantation (FMT); No Intervention.. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "* Patients must have a confirmed diagnosis of TNBC (defined as estrogen receptor expression 0-10%, progesterone receptor expression 0-10%, and HER-2/neu negative (immunohistochemistry 0, 1+, or 2+ and fluorescent in-situ hybridization negative for HER-2 gene amplification) and are about to start neo". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: FRIDA
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07292142
- Phase: 1/2
- Setting: FMT in Triple Negative Breast Cancer Guided by ctDNA
- Sponsor: Jewish General Hospital
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT07292142: https://clinicaltrials.gov/study/NCT07292142

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07292142.json